T1	Participants 34 101	patients receiving androgen deprivation therapy for prostate cancer
T2	Participants 185 210	advanced prostate cancer,
T3	Participants 357 410	atients with prostate cancer during androgen ablation
T4	Participants 753 848	Forty-eight osteoporotic patients with prostate cancer, treated with 3-month depot triptorelina
